The growth and metastasis of human, HER-2/neu-overexpressing tumor cell lines in male SCID mice

Breast Cancer Research and Treatment

Volumn 61, Issue 3, 2000, Pages 217-228

  Clinchy, Birgitta ^a,b   Gazdar, Adi ^c   Rabinovsky, Rosalia ^a,d   Yefenof, Eitan ^a,d   Gordon, Brian ^e   Vitetta, Ellen S ^a,e  

^a Cancer Immunobiology Center   (United States)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d HEBREW UNIVERSITY   (Israel)

^e CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Her 2 neu; In vivo tumor models; Metastasis; SCID mice; Soluble Her 2

Indexed keywords

IMMUNOTOXIN; MATRIGEL; MONOCLONAL ANTIBODY;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DEATH; GENE OVEREXPRESSION; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IRRADIATION; LUNG INFILTRATE; LUNG METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; ONCOGENE NEU; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SCID MOUSE;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL DIVISION; DNA PRIMERS; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; INJECTIONS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, SCID; PHENOTYPE; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0033868727     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006494001861     Document Type: Article

References (52)

1. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
2. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
3. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
4. Increased expression of the putative growth factor receptor p185(HER2) causes transformation and tumorigenesis of NIH 3T3 cells
5. ERBB2 oncogene in human breast cancer and its clinical significance
6. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues
7. HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer
8. Preclinical testing of an anti-erb B-2 recombinant toxin
9. Phase II study of weekly intravenous recombinant humanized anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
10. Monoclonal antibodies directed to the erbB-2 receptor inhibit in viva tumour cell growth
11. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
12. Prolonged survival of mice with human gastric cancer treated with an anti-c-erbb-2 monoclonal antibody
13. Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines
14. Evidence of functional lymphocytes in some (leaky) SCID mice
15. Isolation of two human tumor epithelial cell lines from solid breast carcinomas
16. Breast tumor cell lines from pleural effusions
17. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer
18. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by EIA
19. In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product
20. Quantitative polymerase chain reaction for human herpesvirus diagnosis and measurement of Epstein-Barr virus burden in posttransplant lymphoproliferative disorder
21. ERBB-2 (HER2/neu) gene copy number, p185(HER-2) overexpression, and intratumor heterogeneity in human breast cancer
22. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells
23. In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells
24. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene
25. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast can
26. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice
27. Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice
28. Behavior of tumors produced by transplantation of human mammary cell lines in athymic nude mice
29. Radiolabeled antibody targeting of the HER-2/neu oncoprotein
30. 1995. Supression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake
31. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells
32. Outgrowth of BT-474 human breast cancer cells in immune-deficient mice: A new in viva model for hormone-dependent breast cancer
33. Recombinant humanized anti-HER2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
34. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines
35. ErbB-2 expression in estrogen-receptor-positive breast-tumor cells is regulated by growth-modulatory reagents
36. Metastasis from human breast cancer cell lines
37. Potential of the SCID mouse as a host for human tumors
38. 1992. Comparative studies between nude and SCID mice on the growth and metastatic behavior of xenografted human tumors
39. Use of immunodeficient mice in metastasis research
40. Quantitative comparison between the transplantability of human and murine tumors into the subcutaneous tissue of NCr/Sed-nu/nu nude and severe combined immunodeficient mice
41. Growth and metastasis of human breast carcinoma with Matrigel in athymic mice
42. The extra-cellular domain of p185-neu is released from the surface of human breast carcinoma cells, SK-BR-3
43. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients
44. Prognostic significance of p105 (c-erbB-2, HER2/neu) serum levels in patients with ovarian cancer
45. Tissue expression and serum levels of HER-2/neu in patients with breast cancer
46. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro
47. Post-surgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice
48. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo
49. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
50. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities
51. Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: Comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl) benzoate radioiodination methods
52. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis